Medical Cannabis Formulations, Administration Routes, and Dosing: Perspectives of Patients With Cancer Who Consume [0.03%]
癌症患者的医用大麻配方、给药途径和剂量：视角研究
Manan M Nayak,Peter R Chai,Stephanie Tung et al.
Manan M Nayak et al.
Purpose: Medical cannabis (MC) is used by 1 in 3 patients with cancer. Scientific work suggests a disconnect between patients' cannabis therapeutics practices and oncologists' clinical preferences. This qualitative study ...
Experimental Evidence of Dexamethasone in Reversing Endothelial Dysfunction in COVID-19: Therapeutic Insights from Intranasal Administration [0.03%]
地塞米松逆转COVID-19内皮功能障碍的实验证据：鼻腔给药治疗的新思路
Celeste Trejo-Moreno,Marisol Méndez-Martínez,Zimri A Alvarado-Ojeda et al.
Celeste Trejo-Moreno et al.
Purpose: Vascular endothelial dysfunction (ED) plays a critical role in the pathogenesis of severe COVID-19. Intranasal dexamethasone (IN-DXM) has been reported to improve clinical outcomes more efficiently than intraveno...
Leukocytoclastic Vasculitis and Profound Cytopenias Following Teicoplanin Therapy: A Case Report on Glycopeptide Cross-Reactivity [0.03%]
替考拉宁引起的白细胞破裂性血管炎及重度骨髓抑制的病例报告：糖肽类药物交叉过敏反应导致的一例并发症
Qimei Wei,Wen Jiang,Xinshuang Chen et al.
Qimei Wei et al.
Purpose: To report a case of teicoplanin-induced leukocytoclastic vasculitis with concurrent bicytopenia. Methods: A 61-year-old male w...
Recognizing Arthralgia as a Potential Adverse Effect of CFTR Modulators: A Case Report [0.03%]
囊性纤维化转导子调节剂的关节痛不良反应报告病例分析
Flora Charbonneau,Magali Dupuy-Grasset,Jeanne Languepin et al.
Flora Charbonneau et al.
Ruth Fisher
Ruth Fisher
Purpose: The increasing legalization and use of cannabis necessitate robust, standardized methods for identifying and characterizing cannabis users in research and clinical settings. Variability in user demographics, cons...
Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer [0.03%]
新型推进剂布地奈德/甘羟铝/福莫特罗粉吸入剂与氢氟烷烃134A推进剂的暴露量相当：使用储雾器的压力气雾剂递送方式
Hitesh Pandya,Mehul Patel,Michael Gillen et al.
Hitesh Pandya et al.
Purpose: Hydrofluoroalkane-134a (HFA-134a), the propellant in the marketed budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) formulation, has a global warming potential (GWP) that falls above environmental reg...
High Adherence to Repeat Multitarget Stool DNA Testing and Follow-Up Colonoscopy in Average-Risk United States Adults: Results from a Nationally Insured Cohort [0.03%]
美国一般风险成人中结肠镜检查前重复多次目标粪便DNA检测的高依从性：来自全国受保队列的结果
Mallik Greene,Shrey Gohil,Juliana Vanessa Rincón López et al.
Mallik Greene et al.
Purpose: Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the United States, despite available screening programs, making regular screening essential for early detection and prevention. This study ev...
Bioequivalence and Safety Study of Ranolazine Extended-Release Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Pharmacokinetic Study [0.03%]
空腹及餐后条件下拉诺利嗪缓释片与原研药在中国健康受试者中生物等效性和安全性比较的随机、开放、单剂量、自身交叉I期药物代谢动力学研究
Xing Chen,Yaming Li,Genshan Ma
Xing Chen
Purpose: The bioequivalence of the generic (Test formulation, T) and the originator (Reference formulation, R) ranolazine extended-release tablets was assessed in Chinese healthy subjects under fasting and fed conditions....
Letter to The Editor, Regarding "Indirect Comparison of Maralixibat and Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis" Recently Published by Lacey and Colleagues [0.03%]
致编辑的信：评论Lacey等人最近发表的文章“Maralixibat与Odevixibat治疗进行性家族性肝内胆汁淤积症的间接比较”
Emmanuelle Kaltenbach,Virginie Jacquemin,Luis Briseño-Roa et al.
Emmanuelle Kaltenbach et al.